The largest drug
discovery company
in the CEE region

More

Your integrated drug
discovery partner of choice

More

Developing breakthrough
therapies in oncology

More

Delivering comprehensive
research solutions to biotech
and pharma

More

News See all

Selvita to exhibit at the 20th Annual Drug Discovery…

Krakow, Poland – 5 June 2019 – Selvita, drug discovery and development partner for the pharmaceutical and biotechnology industries, will...
More

Selvita present at the EFMC-ACSMEDI MedChem Frontiers 2019 Conference

Krakow, Poland – 3 June 2019 – Selvita, a clinical stage drug discovery and development company focused on innovative medicines...
More

Selvita at the Annual BIO International Convention 2019

Krakow, Poland – 28 May 2019 – Selvita (WSE: SLV), a clinical stage drug discovery and development company focused on...
More

Selvita Reports First Quarter 2019 Financial Results and Provides…

- Investigational New Drug (IND) application to conduct a Phase 1 study of selective CDK8 inhibitor SEL120 cleared by U.S....
More

Selvita announces availability of abstracts regarding Phase 1/2 study…

Krakow, Poland - 16 May 2019 - Selvita today announced that abstracts regarding Phase 1/2 study of SEL24/MEN1703 accepted for...
More

About Selvita

Selvita has two primary focus areas:

– to serve the drug discovery market as a customer centric provider of high quality, integrated drug discovery services and

– as a drug discovery company engaged in the research and development of breakthrough therapies in oncology.

More

Drug Discovery Services

Selvita is a global integrated drug discovery partner for the pharmaceutical and biotechnology industries.

We offer drug discovery support at every stage of the early discovery phase up to the preclinical research phase.

More

Research and Development

In its internal research and development efforts, Selvita focuses on different dimensions of oncology.

The company’s most advanced R&D program is SEL24, a dual PIM/FLT3 kinase inhibitor currently in Phase I/II clinical study, in acute myeloid leukemia.

More

Investor Relations SLV 1,2000 PLN ( 2,01% )

Share price 2019-07-23 17:00:00

61,0000 PLN More

Careers

We are a multicultural and a multinational company employing professionals from all over the world.

Find out who we’re courrently looking for and what we can offer our employees.

More